FDA’s menthol ban and vaping restrictions will have consequences

CONTACT:
Jeff Stier
Senior Fellow
Consumer Choice Center
[email protected]

FDA’s menthol ban and vaping restrictions will have consequences

WASHINGTON, D.C. – Last week, FDA Commissioner Scott Gottlieb announced severe sales and flavor restrictions on vaping products and introduced a new ban on menthol flavors in combustible tobacco products.

Reacting to the news, Consumer Choice Center senior fellow Jeff Stier said the plan is riddled with flaws.

“Banning menthol cigarettes will lead to increased youth smoking, especially in minority communities, where a ban would spark illegal markets reminiscent of the days of alcohol prohibition,” said Stier.

Writing in USA Today, he pointed out that various civil rights and police organizations have come out united against the policy, stating that is is both discriminatory toward minority communities and would eat up precious time and resources for police officers.

“When Congress gave the FDA authority to regulate recreational lower-risk nicotine products, it was with the expectation that the FDA would be able to both discourage youth use and help adults quit smoking. Sadly, to date, the FDA has accomplished little on either front,” said Stier.

“These failures don’t justify a misplaced “crackdown” on e-cigarettes and responsible sellers. They require an aggressive effort to stop the bad actors. Accomplishing that now will require a new FDA policy. And clearly, a new commissioner,” he added.

“The FDA should instead concentrate on two primary goals: Enforce already-existing rules that ban the sale of e-cigarettes to minors, and, as recommended by the American Cancer Society, support adult smokers who attempt to quit with e-cigarettes.”

***CCC Senior Fellow Jeff Stier is available to speak with accredited media on consumer regulations and consumer choice issues. Please send media inquiries HERE.***

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org.

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

FDA to target underage tobacco use in new effort

ARKANSAS DEMOCRAT GAZETTE: Gottlieb, in pursuing his tobacco strategy, is taking some flak from fellow conservatives. “The administration promised less regulation — without sacrificing protections,” said Jeff Stier, a senior fellow at the Consumer Choice Center. “So if the FDA fails to meet both objectives — by announcing a heavy-handed regulatory plan — President [Donald] Trump should realize that the current leadership at the FDA is not equipped to implement the administration’s policy agenda.”

READ MORE

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

FDA Unveils Anti-Tobacco Measures

VALLEY NEWS: Gottlieb, in pursuing his tobacco strategy, is taking some flak from fellow conservatives. “The administration promised less regulation — without sacrificing protections,” said Jeff Stier, a senior fellow at the Consumer Choice Center. “So if the FDA fails to meet both objectives — by announcing a heavy-handed regulatory plan — President Trump should realize that the current leadership at the FDA is not equipped to implement the administration’s policy agenda.” But Gottlieb’s boss, Health and Human Services Secretary Alex Azar signaled his support for the FDA in a statement.

READ MORE

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

FDA announces sweeping new regulations on e-cigarette sales

UPS: But Gottlieb has received some pushback from consumer groups.

“The administration promised less regulation — without sacrificing protections,” said Jeff Stier, a senior fellow at the Consumer Choice Center, the Washington Post reported. “So if the FDA fails to meet both objectives — by announcing a heavy-handed regulatory plan — President Trump should realize that the current leadership at the FDA is not equipped to implement the administration’s policy agenda.”

READ MORE

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

FDA unveils sweeping anti-tobacco effort to reduce underage vaping and smoking

THE WASHINGTON POST: Gottlieb, in pursuing his tobacco strategy, is taking some flak from fellow conservatives. “The administration promised less regulation — without sacrificing protections,” said Jeff Stier, a senior fellow at the Consumer Choice Center. “So if the FDA fails to meet both objectives — by announcing a heavy-handed regulatory plan — President Trump should realize that the current leadership at the FDA is not equipped to implement the administration’s policy agenda.” But Gottlieb’s boss, Health and Human Services Secretary Alex Azar signaled his support for the FDA in a statement.

READ MORE

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

The Science-Based Community and E-Cigarettes

Government agencies populated with scientists people are pleased to call “experts” are often thought to be above the ordinary give-and-take of politics and, especially, immune to the clarion calls of activists and pressure of public opinion. Scientific experts, or “the science-based community,” is supposed to be driven by data and evidence, not the naked pressure of agenda driven interests. As we will see in the case of the Food and Drug Administration’s relationship to e-cigarette regulation, these assumptions about the impartiality of scientists don’t always hold water.

The FDA is readying a new action plan to be announced soon concerning e-cigarettes. Nobody knows what the agency will do. But it really shouldn’t be so complicated.

E-cigarettes are not entirely safe and they should not be used by kids.

At the same time, combustible cigarettes are around 95 percent more dangerous than e-cigarettes. Many adults who have not been able to quit smoking using other methods have now completely quit with the help of a wide variety of these far-less harmful non-combustible alternatives.

The FDA must finally formulate sensible, science-based policies to achieve two key goals:

1) Enforce existing rules that ban the sale of e-cigarettes to minors.

2) Support adult smokers who attempt to quit with e-cigarettes, as recommended by the American Cancer Society.

The FDA says that because of “news reports,” public opinion, and data about youth use that the agency hasn’t released, it is threatening to take draconian steps to make e-cigarettes less appealing and harder to get for adult smokers. The Washington Post reported on Thursday that the agency plans to remove e-cigarette pods and flavored e-cigarettes from most outlets until a manufacturer applies for and receives approval for each product. The agency is also warning that it may ban sales everywhere except in vape shops.

This posture represents a dramatic and surprising reversal from July 2017, when the agency announced a new “comprehensive regulatory plan” for tobacco products, including e-cigarettes, which embraced the idea of tobacco harm reduction.

Commissioner Scott Gottleib, M.D., stated that the plan required “demonstrating a greater awareness that nicotine—while highly addictive—is delivered through products that represent a continuum of risk and is most harmful when delivered through smoke particles in combustible cigarettes.” In other words, we should be more concerned about the smoke delivery system than we are about nicotine itself.

As part of that plan, the FDA extended the application deadline in order to give the agency time to first issue “foundational rules to make the product review process more efficient, predictable, and transparent for manufacturers.” Although the FDA has failed to establish those rules, it is now threatening to undo the extension by fiat.

Commissioner Gottlieb spoke clearly last year, explaining that, “Unless we change course, 5.6 million young people alive today will die prematurely later in life from tobacco use.” As the FDA has stated, cigarette smoking is by far the leading cause of tobacco-related disease.

Gottlieb continued, “Envisioning a world where cigarettes would no longer create or sustain addiction, and where adults who still need or want nicotine could get it from alternative and less harmful sources, needs to be the cornerstone of our efforts—and we believe it’s vital that we pursue this common ground.”

But in the last two months, under intense pressure from activists, the FDA has abandoned that common ground. Instead, it is pitting the proper goal of preventing youth use against the other proper goal of helping adult smokers quit. These goals are not and cannot be seen as mutually exclusive.

The news reports and the public opinion the FDA is largely relying upon to justify this about-face have been generated by pressure groups who want non-medicinal nicotine products off the market entirely.

Sound science isn’t an obstacle for those hell-bent on removing e-cigarettes from the market. Consider the latest creepy video from a group known as “The Truth,” featuring puppets, which at once seems to target kids, journalists, and politicians alike. The text under the video states that vaping “…MAKES YOU 4X MORE LIKELY TO START SMOKING CIGARETTES.”

Actually, the latest study, by Rand, concludes otherwise: “EC use among youth is prospectively associated with progression toward greater cigarette use.” Are kids who engage in risky behaviors such as vaping also more likely to start smoking? Absolutely. Does vaping “make” or cause youth to start smoking? That’s not what the evidence says.

The Truth knows better than to confuse association with causation…at least accidentally.

Can’t we agree that kids absolutely shouldn’t use e-cigarettes without intentionally misleading kids by exaggerating the risks? Meanwhile, reporters were the real puppets, repeating unsupported assertions without scrutiny. This, in turn, has led to distorted public opinion. And as the FDA now concedes, that opinion contributed to its threatened reversal on e-cigarettes.

But it’s not too late. In its new plan, the FDA should implement this rational common ground by taking the following three steps:

1) Focus on the bad actors. The FDA should act swiftly and forcefully, as it has the authority to do, against any retailer caught selling an e-cigarette to a minor. In an October 31st announcement, the agency properly acknowledged it must do more, including preventing youth access through social sources.

2) The FDA must work constructively with the industry it regulates. Reports indicate it has begun doing so, to prevent youth initiation, while at the same time permitting recreational nicotine products not only to remain on the market but to be developed to appeal to adult smokers. To do so, it should announce long-promised product standards which would allow the private sector to develop and then market lower-risk nicotine products to attract even more adult smokers. Those standards should distinguish between sweet flavors which adults also enjoy and the marketing of those flavors. There’s no need, for example, to label sweet flavored e-cigarettes “gummy bear.”

3) Make good on the promise to change misconceptions about nicotine, which, while addictive, is not the major cause of tobacco-related disease. Everyone should have a right to accurate information about the risks of vaping, including the risks as compared to smoking, as Public Health England has donewith much success.

What should FDA not do?

1) Remove e-cigarettes from any outlet, such as convenience stores and gas stations, where adults regularly purchase the e-cigarettes that made them non-smokers. Vape shops offer valuable quit-smoking advice and are generally among the most responsible vendors. But convenience stores are, well, convenient. Quitting is hard enough as it is. We should want lower-risk products to be available to adult smokers in the same places they have been buying their cigarettes for decades.

Further, collective punishment of entire classes of retailers punishes the responsible vendors who are necessary to implement widespread harm reduction.

2) Allow either side to erode common ground. Just as the FDA shouldn’t be lenient with those who sell or give e-cigarettes to kids, it shouldn’t allow false assertions about the risks of e-cigarettes to stand unchallenged. Misleading statements influence policy-making, even if only by distorting public opinion. Worse, campaigns which exaggerate the risks of e-cigarettes harm public health by giving adult smokers all they need not to try quitting: another excuse.

3) Fall prey to the notion that the FDA has in its power the ability prevent every last youth from every trying an e-cigarette. Commissioner Gottlieb said in September: “It’s now clear to me, that in closing the on-ramp to kids, we’re going to have to narrow the off-ramp for adults who want to migrate off combustible tobacco and onto e-cigs.”

Completely preventing youth from experimenting with risky products is impossible. It was impossible in the days of prohibition and it is even more impossible today. Products which appeal to youth also appeal to adult smokers. And products which don’t appeal to youth, won’t appeal to many adult smokers. This is why stores like Walgreens are permitted to offer fruit flavored nicotine gum, even without a prescription. Kids generally don’t buy it. Neither do most smokers.

Design appeal, a variety of flavors, and availability are all necessary components to effectively implement tobacco harm reduction for adult smokers. What’s not necessary is allowing kids to buy or use them.

When giving the FDA authority to regulate recreational lower-risk nicotine products, Congress believed the FDA could be sophisticated enough to at once prevent youth use while helping adults quit smoking. Sadly, to date, the FDA has accomplished little on either front. These failures don’t justify a misplaced “crackdown” on e-cigarettes and responsible sellers. They require an intensive focus on stopping the bad actors.

If the FDA doesn’t get it right— this month—President Trump should ask Gottlieb, in an exit interview, why the agency couldn’t achieve a central promise of the Trump presidency: improve our lives not with more regulation, but with less of it, wisely implemented.

This could very well be another case where the common sense instincts of an elected politician trump the scientific instincts of scientists trying to apply them within a political context. Scientific and political expertise, after all, is not the same thing.

Originally published at https://www.amgreatness.com/2018/11/13/the-science-based-community-and-e-cigarettes/

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

Jeff Stier: If FDA doesn’t get it right on vaping, Gottlieb should go

CONTACT:
Jeff Stier
Senior Fellow
Consumer Choice Center
[email protected]

Jeff Stier: If FDA doesn’t get it right on vaping, Gottlieb should go

WASHINGTON, D.C. – In an article published on American Greatness, Jeff Stier, senior fellow at the Consumer Choice Center, brings attention to the FDA’s move to restrict vaping and e-cigarette flavors and calls on Trump to bring FDA Commissioner Scott Gottlieb to task if he doesn’t get vaping regulations right.

“If the FDA doesn’t get it right— this month— President Trump should ask, in an exit interview, why Gottlieb couldn’t achieve a central promise of the administration: improving our lives not with more regulation, but with less of it, wisely implemented,” said Stier.

“We should all be able to agree that E-cigarettes are not entirely safe and should not be used by kids.

“At the same time, as Public Health England has been saying for more than three years, e-cigarettes are around 95% less harmful than combustible cigarettes and can help smokers quit.

In its new plan, the FDA should implement the legitimate common ground by taking the following three steps:

1: Focus on the bad-actors. The FDA should act swiftly and forcefully, as it has the authority to do, against any retailer caught selling an e-cigarette to a minor.

2: The FDA must work constructively with the industry it regulates.

3: Make good on the promise to change misconceptions about nicotine, which, while addictive, is not the major cause of tobacco-related disease.

What should FDA not do?

1: Remove e-cigarettes from all stores except vape shops.

2: Allow either side to erode common ground. Just as the FDA shouldn’t be lenient with those who sell or give e-cigarettes to kids, it shouldn’t allow false assertions about the risks of e-cigarettes to stand unchallenged.

3: Fall prey to the notion that the FDA has in its power the ability to prevent every last youth from every trying an e-cigarette.

When giving the FDA authority to regulate recreational lower-risk nicotine products, Congress believed the FDA could be sophisticated enough to at once prevent youth use while helping adults quit smoking.

Sadly, to date, the FDA has accomplished little on either front. These failures don’t justify a misplaced “crackdown” on e-cigarettes. They require an intensive focus on stopping the bad actors,” said Stier.

***CCC Senior Fellow Jeff Stier is available to speak with accredited media on consumer regulations and consumer choice issues. Please send media inquiries HERE.***

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org.

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

Common Ground Will Rescue Us From E-cigarette and Vape Wars

CONTACT:

Jeff Stier
Senior Fellow
Consumer Choice Center
[email protected]

Common Ground Will Rescue Us From E-cigarette and Vape Wars

WASHINGTON – As the midterm elections wrap up across the country, the FDA is readying its new action plan concerning e-cigarettes.

Jeff Stier, senior fellow at the Consumer Choice Center, offers these simple steps to follow if the FDA wants to adhere to common ground:

“We should all be able to agree that E-cigarettes are not entirely safe and should not be used by kids,” said Stier.

“At the same time, as Public Health England has been saying for more than three years, e-cigarettes are around 95% less harmful than combustible cigarettes and can help smokers quit.

To maximize protection to Americans of all ages, the FDA must finally formulate sensible, science-based policies to achieve two key goals:

  • Prevent youth from initiating the use of any nicotine-containing product, including e-cigarettes.
  • Foster switching by adult smokers who have been unable to quit by other means.

The FDA is threatening that because of “news reports,” public opinion and data about youth use that the agency hasn’t released, it may soon remove many e-cigarettes from the market, including most flavors, as well as the pods they come in, until a manufacturer applies for and receives approval for each product.

The agency is also warning that it may ban sales everywhere except in vape shops.

But it’s not too late. In its new plan, the FDA should implement the legitimate common ground by taking the following three steps:

1: Focus on the bad-actors. The FDA should act swiftly and forcefully, as it has the authority to do, against any retailer caught selling an e-cigarette to a minor.

2: The FDA must work constructively with the industry it regulates.

3: Make good on the promise to change misconceptions about nicotine, which, while addictive, is not the major cause of tobacco-related disease.

What should FDA not do?

1: Remove e-cigarettes from all stores except vape shops.

2: Allow either side to erode common ground. Just as the FDA shouldn’t be lenient with those who sell or give e-cigarettes to kids, it shouldn’t allow false assertions about the risks of e-cigarettes to stand unchallenged.

3: Fall prey to the notion that the FDA has in its power the ability to prevent every last youth from every trying an e-cigarette.

When giving the FDA authority to regulate recreational lower-risk nicotine products, Congress believed the FDA could be sophisticated enough to at once prevent youth use while helping adults quit smoking.

Sadly, to date, the FDA has accomplished little on either front. These failures don’t justify a misplaced “crackdown” on e-cigarettes. They require an intensive focus on stopping the bad actors.

If the FDA doesn’t get it right— this month— President Trump should ask, in an exit interview, why FDA leadership couldn’t achieve a central promise of the administration: improving our lives not with more regulation, but with less of it, wisely implemented,” said Stier.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org.

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.

WHO’s afraid of vaping?

For the second time in two years, I sat in the public gallery at a United Nations conference in Geneva as a senior UN bureaucrat told us that all members of the media and public were barred from the proceedings, writes Yael Ossowski for Spiked. This particular occasion was one of the UN’s biannual sessions to update the World Health Organisation’s Framework Convention on Tobacco Control.

The FCTC is the first global-health treaty enacted by WHO. It has been ratified by 181 countries and forms the basis of a number of national laws across the globe, such as tobacco taxes, advertising restrictions, and plain cigarette packaging.

Each biannual meeting is a taxpayer-financed talkfest, dominated by various health ministries and anti-tobacco organisations like the Campaign for Tobacco-Free Kids and the Framework Convention Alliance, who are not only granted ‘observer status’, but also intervene in the large plenary debates and use their platform to shame the delegates of any country that doesn’t adopt a prohibitionist attitude toward tobacco.

Though the conference claims to be about science and public health, it is anything but.

For instance, new vaping and e-cigarette technologies are the most popular stop-smoking aids in England, used by 1.2million Brits according to the latest government figures. A Public Health England report says that vaping can reduce health risks by 95 and can increase the chances of quitting smoking by up to 50%.

But the arguments for vaping are dismissed by WHO as ‘unfounded’ and ‘inconclusive’. One top NGO said parties at the meeting should ‘refrain from engaging in lengthy and inconclusive discussion’ on alternative nicotine products like vaping.

Vaping activists had tried to attend the conference to share their stories of how they quit smoking. Volunteers from the International Network of Nicotine Consumer Organisations proudly blew clouds of water vapour outside the conference’s doors. Unlike the more prohibitionist NGOs, they were denied observer status.

The clear anti-vaping bias led to some absurd claims.

Anne Bucher, director-general of the EU’s Health and Food Safety Directorate, was adamant that, despite containing no tobacco, vaping and e-cigarette devices should be considered ‘tobacco products’, subject to all the same laws, restrictions, and bans.

The treaty itself sought to enforce the same restrictions on vaping and e-cigarettes as cigarettes and cigars. This could actually hamper people’s ability to quit smoking.

Another object of hate was the media. Delegates from countries including China, Zimbabwe, the Maldives and Uganda claimed the entire conference should take place without media or public scrutiny. ‘What we’re dealing with is the mafia’, said the delegate from Afghanistan, referring to the public sat in the gallery above.

A representative from Chad lamented that more people did not know about the FCTC meeting and its impact. In the same breath, he argued in favour of kicking out the public and media after the opening plenary.

It was a bizarre and Orwellian conference. The proposals that emerged in the name of protecting public health could seriously set back the improvements in public-health that have come about thanks to alternatives to cigarettes like vaping, e-cigarettes and snus.

One thing became clear: innovative products, new markets and the much hated ‘industry’ were doing more to bring about better health outcomes than the UN’s supranational health bureaucracy.

* Yaël Ossowski is a Canadian journalist and deputy director of the Consumer Choice Center.

mm

About Yaël Ossowski

Yaël Ossowski is a journalist, activist, and writer. He's currently deputy director at the Consumer Choice Center, and senior development officer for Students For Liberty. He was previously a national investigative reporter and chief Spanish translator at Watchdog.org, and worked at newspapers and television stations across the country. He received a Master’s Degree in Philosophy, Politics, Economics (PPE) at the CEVRO Institute in Prague. Born in Québec and raised in the southern United States, he currently lives in Vienna, Austria.

Daily on Healthcare, presented by PhRMA: Trump likely to preview Medicare negotiation in speech at HHS

WASHINGTON EXAMINER: “I expected the administration to have a de-regulatory policy as they have done at other agencies like the EPA,” said Jeff Stier, senior fellow at the consumer advocacy group Consumer Choice Center. “I expected that approach [at EPA] that we can protect the environment while still cutting regulations. Why can’t the FDA do the same?”

READ MORE

mm

About Jeff Stier

Jeff Stier is a Senior Fellow at the Consumer Choice Center. Mr. Stier has been a frequent guest on CNBC, and has addressed health policy on CNN, Fox News Channel, MSNBC, as well as network newscasts. He is a guest on over 100 radio shows a year, including on NPR and top-rated major market shows in cities including Boston, Philadelphia, and Sacramento, plus syndicated regional broadcasts. Jeff’s op-eds have been published in top outlets including The Wall Street Journal, The Los Angeles Times, The New York Post, Forbes, The Washington Examiner, and National Review Online.